Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9996189 | 0.90 | S1PR1 (0.50) | S1PR1TBK1 | |
| SCHEMBL15511423 | 0.80 | TBK1 (0.44) | TBK1NPC1RAB9AATMKMT2A | |
| SCHEMBL177437 | 0.77 | PLA2G2A (0.53) | S1PR1 | |
| SCHEMBL12269410 | 0.73 | S1PR1 (0.60) | S1PR1NPC1RAB9AKMT2A | |
| SCHEMBL9996158 | 0.70 | TBK1 (0.50) | TBK1NPC1RAB9AKMT2A | |
| SCHEMBL6616917 | 0.68 | S1PR5 (0.60) | S1PR1 | |
| SCHEMBL177052 | 0.66 | S1PR1 (0.64) | S1PR1 | |
| SCHEMBL177371 | 0.65 | TBK1 (0.55) | TBK1NPC1RAB9AKMT2A | |
| SCHEMBL16695370 | 0.64 | S1PR5 (0.61) | S1PR1 | |
| SCHEMBL15564870 | 0.64 | ENPP2 (0.53) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | disclosed |
| US-8592399-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2013-11-26 | — | — | US | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| EP-2344484-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885TBK1 731/4885NPC1 931/4885 |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885TBK1 731/4885NPC1 931/4885 |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885TBK1 449/4885NPC1 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.